论文部分内容阅读
作者采用生物素－链亲和素酶联免疫吸附试验方法，对１６４例消化道癌症病人血清ＣＡ２４２水平进行测定。结果，胰腺癌病人血清ＣＡ２４２含量最高（２８６．２±１２５．３Ｕ／ｍｌ），诊断阳性率为７６．９％，特异性为９１．２％；结直肠癌病人为１９３．６±１０６．４Ｕ／ｍｌ，诊断阳性率为６８．９％，特异性为８４．９％；与正常人及其它癌症病人比较，有非常显著性差异（Ｐ＜０．０１）。肝癌组为８６．１±３５．７Ｕ／ｍｌ，胃癌组为３７．６±１６．３Ｕ／ｍｌ，与正常对照组比较亦有显著性差异（Ｐ＜０．０５），但其敏感性仅分别为５８．３％和３２．３％。手术后病情明显缓解的病人，其血清ＣＡ２４２水平明显降低，与病情恶化或复发病人相比，有非常显著性差异（Ｐ＜０．０１）。其它癌症与良性疾病者血清ＣＡ２４２水平无显著性差异（Ｐ＞０．０５）。表明血清ＣＡ２４２水平测定对胰腺癌及结直肠癌的诊断、鉴别诊断、疗效观察和预后评估有一定价值。
The authors used a biotin-streptavidin enzyme-linked immunosorbent assay to measure the serum CA242 levels in 164 patients with digestive tract cancer. Results: The serum CA242 level was highest in pancreatic cancer patients (286.2±125.3 U/ml), the diagnostic positive rate was 76.9%, the specificity was 91.2%, and the colorectal cancer patients were 193.6±106.4 U. The positive rate of diagnosis was 68.9%, and the specificity was 84.9%. There was a significant difference between normal and other cancer patients (P<0.01). The liver cancer group was 86.1±35.7 U/ml, and the gastric cancer group was 37.6±16.3 U/ml. There was also a significant difference compared with the normal control group (P<0.05), but the sensitivity was only different. It is 58.3% and 32.3%. Patients with significantly relieved conditions after surgery had significantly lower serum CA242 levels, which was significantly different from patients with worsening or relapsed disease (P<0.01). There was no significant difference in serum CA242 levels between other cancers and benign diseases (P>0.05). It is indicated that serum CA242 levels have a certain value for the diagnosis, differential diagnosis, curative effect observation and prognosis evaluation of pancreatic cancer and colorectal cancer.